Related Experiment Video
Updated: May 13, 2025
Isolation of Murine Peritoneal Macrophages to Carry Out Gene Expression Analysis Upon Toll-like Receptors Stimulation
Published on: April 29, 2015
Small peritoneal macrophages are accelerators of peritoneal metastasis of colorectal cancer
Wanli Yang1, Feng Jiang1, Lixia Xu1
1Translational Institute for Cancer Pain, Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, China.
Background:
The peritoneal cavity (PerC) constitutes a distinct anatomical compartment that harbors various subpopulations of peritoneal macrophages. However, there remains a significant gap in our understanding of the functions of these macrophage subpopulations in the context of peritoneal metastasis of colorectal cancer (PM-CRC) and their roles in the tumor progression process. This investigation seeks to analyze the characteristics of large peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs), in the context of PM-CRC.
Methods:
A murine model of PM-CRC was developed through the intraperitoneal administration of the MC38 colorectal cancer cell line into C57BL/6 mice. Peritoneal effusions were subsequently collected at various time points post-injection and subjected to analysis via flow cytometry, cell co-culture assays, among other techniques. Additionally, clodronate liposomes were employed to deplete peritoneal macrophages in order to investigate the impact of SPMs on tumor progression and survival in the PM-CRC mouse model.
Results:
The findings of this study demonstrated a significant increase in the number of SPMs during the progression of PM-CRC, concomitant with a decrease in the proportion of LPMs. Notably, SPMs exhibited a macrophage phenotype conducive to tumor growth. In the PM-CRC mouse model, the dynamic escalation of SPMs following lipopolysaccharide stimulation was associated with a reduced survival rate. However, the depletion of SPMs using clodronate liposomes in the later stages of the model effectively extended the survival period in cases of PM-CRC.
Conclusions:
The findings of this study suggest that SPMs acts as a catalyst in the progression of peritoneal metastasis in colorectal cancer, thereby identifying it as a potential therapeutic target for managing this condition.
Insights
Small peritoneal macrophages (SPMs) promote colorectal cancer metastasis in the peritoneum. Depleting SPMs extended survival in a mouse model, identifying them as a potential therapeutic target for peritoneal metastasis of colorectal cancer (PM-CRC).
Area of Science:
- Immunology
- Oncology
- Gastroenterology
Background:
- The peritoneal cavity contains diverse macrophage subpopulations, including large peritoneal macrophages (LPMs) and small peritoneal macrophages (SPMs).
- The specific roles of these peritoneal macrophage subpopulations in colorectal cancer peritoneal metastasis (PM-CRC) and tumor progression remain largely uncharacterized.
Purpose of the Study:
- To investigate the characteristics and functions of LPMs and SPMs in the context of PM-CRC.
- To determine the impact of SPMs on tumor progression and survival in a murine model of PM-CRC.
Main Methods:
- Development of a murine model of PM-CRC via intraperitoneal administration of MC38 colorectal cancer cells.
- Analysis of peritoneal effusions using flow cytometry and cell co-culture assays.
- Macrophage depletion using clodronate liposomes to assess the role of SPMs in tumor progression and survival.
Main Results:
- PM-CRC progression was associated with an increased proportion of SPMs and a decreased proportion of LPMs.
- SPMs displayed a pro-tumorigenic phenotype, and their escalation correlated with reduced survival in the PM-CRC model.
- Depletion of SPMs in later stages of PM-CRC significantly extended survival.
Conclusions:
- SPMs act as key drivers in the progression of peritoneal metastasis in colorectal cancer.
- SPMs represent a promising therapeutic target for managing PM-CRC.
